Amyloidosis News and Research

RSS
Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.
Novel amyloid protein that induces amyloidosis discovered

Novel amyloid protein that induces amyloidosis discovered

Study aims to achieve earlier diagnosis of ATTR cardiac amyloidosis in minority populations

Study aims to achieve earlier diagnosis of ATTR cardiac amyloidosis in minority populations

Researchers identify possible role of polyphosphate in dialysis-related amyloidosis

Researchers identify possible role of polyphosphate in dialysis-related amyloidosis

Study provides new insights into key beneficial function of small ancient protein

Study provides new insights into key beneficial function of small ancient protein

Renal infarction linked with acute kidney injury in patients with cardiac amyloidosis

Renal infarction linked with acute kidney injury in patients with cardiac amyloidosis

Scientists identify promising small molecules that curb errant proteins of AL amyloidosis

Scientists identify promising small molecules that curb errant proteins of AL amyloidosis

Researchers use experimental PET to detect abnormal tau in brains of living former NFL players

Researchers use experimental PET to detect abnormal tau in brains of living former NFL players

Researchers create new accessible staging system to predict survival for patients with AL amyloidosis

Researchers create new accessible staging system to predict survival for patients with AL amyloidosis

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Newly discovered protein shown to cause amyloid-beta plaques in Alzheimer's

Newly discovered protein shown to cause amyloid-beta plaques in Alzheimer's

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

Janssen’s Darzalex receives positive CHMP opinion for treating multiple myeloma patients

Janssen’s Darzalex receives positive CHMP opinion for treating multiple myeloma patients

Alnylam’s patisiran receives positive opinion from CHMP for treating hATTR amyloidosis

Alnylam’s patisiran receives positive opinion from CHMP for treating hATTR amyloidosis

Researchers identify novel mutation in amyloid diseases

Researchers identify novel mutation in amyloid diseases

NNCC selects Stanford Health Care Dialysis Unit as winner of 2018 Advocacy Award

NNCC selects Stanford Health Care Dialysis Unit as winner of 2018 Advocacy Award

BU postdoctoral researcher wins competitive NIH Pathway to Independence Award

BU postdoctoral researcher wins competitive NIH Pathway to Independence Award